Who we are

Med’Inn’Pharma (MIP) is a pre-clinical stage Biotech company that was founded in 2017 as a spin-off from the French blood bank establishment (EFS) and the French National Institute of Health (INSERM). MIP is pioneering the development of a new class of disease modifying therapies dedicated to resolve pathologic inflammation in a wide range of degenerative diseases and conditions intended to positively impacting health span. 

 Our founders are world leaders in immunology and inflammation-resolution and have developed a patent protected process to harness bioactive molecules from propriety conditioned human cells into a stable biologic drug product. This will allow to ‘transplant’ a physiologic and bioactive resoluome* emitted during normal inflammation-resolution phase to pathologic deregulated environments. Our innovative approach works by restoring a complex but healthy/physiologic inflammation-resolution network, reprograms durably macrophages, and ‘fine-tunes’ inflammation-driven degenerative disorders for repair and regeneration and with that durably restore tissue and immune functionality and homeostasis.

 At MIP we are using our know how to revert pathologic inflammation to resolve under physiologic conditions for the development of a new generation of human cell-derived therapeutics with truly disease modifying properties applicable to a wide range of degenerative disorders and diseases. 


*secretome from cells undergoing inflammation-resolution


Sylvain Perruche, PhD

Président, CEO

Mélanie Couturier, PhD

CMC & Drug dev.

Francis Bonnefoy, PhD

Preclinical study

Agathe Depaire, MSC

PhD Student

Amélie Wadel, BSC


Catherine Pletan, PharmD

CMC & Drug dev.

Nicolas Ferry, MD PhD


Francois Brackman, MD


Nadja Prang, PhD


Christophe de Romeuf, PhD